Bio-Techne Corporation (TECH) Presents at Baird Global Healthcare

Core Insights - The company identifies three key end markets: pharmaceuticals (approximately 30% of revenue), smaller biotech (around 20%), and academia (also about 20%) [1] - The pharmaceutical sector is expected to experience a pipeline reshuffling due to the IRA legislation, with anticipated impacts continuing into 2024 but expected to stabilize by 2025 [1] - R&D funding is projected to be allocated more evenly across the portfolio, rather than being heavily focused on early-stage projects [1]